并对所表达的NMDA受体不同亚型的药理学特性进行了研究。
And we studied pharmacological properties of different sub-types of NMDA receptors.
药理学研究初步表明D5B受体与D5受体的药理学特性不同。
The pharmacological study showed that the D5B receptor had distinct pharmacological properties from D5 receptor.
然而，却有相当比例的患者的治疗使用了替非罗班——具有阿昔单抗的部分药理学特性。
However, a large proportion of patients in the community are treated with eptifibatide, an agent that shares some but not all pharmacological properties with abciximab.
应用推荐